IL194900A - HLA allele gene associated with drug antagonism and methods for detecting it - Google Patents
HLA allele gene associated with drug antagonism and methods for detecting itInfo
- Publication number
- IL194900A IL194900A IL194900A IL19490008A IL194900A IL 194900 A IL194900 A IL 194900A IL 194900 A IL194900 A IL 194900A IL 19490008 A IL19490008 A IL 19490008A IL 194900 A IL194900 A IL 194900A
- Authority
- IL
- Israel
- Prior art keywords
- substituted
- patient
- allele
- patients
- drug
- Prior art date
Links
- 108700028369 Alleles Proteins 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims abstract description 35
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 title claims abstract description 12
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims abstract description 9
- 108010058607 HLA-B Antigens Proteins 0.000 claims abstract 6
- 102000006390 HLA-B Antigens Human genes 0.000 claims abstract 6
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims abstract 6
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims abstract 3
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 claims abstract 3
- 229940079593 drug Drugs 0.000 claims description 43
- 239000003814 drug Substances 0.000 claims description 43
- 108091034117 Oligonucleotide Proteins 0.000 claims description 10
- 206010061623 Adverse drug reaction Diseases 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 238000009396 hybridization Methods 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 2
- BMPDWHIDQYTSHX-UHFFFAOYSA-N licarbazepine Chemical compound C1C(O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-UHFFFAOYSA-N 0.000 claims 2
- 229960001816 oxcarbazepine Drugs 0.000 claims 2
- 210000004209 hair Anatomy 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 abstract description 44
- 239000003550 marker Substances 0.000 abstract description 10
- 206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 abstract description 2
- 108010028440 HLA-B*46:01 antigen Proteins 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 description 26
- 239000000523 sample Substances 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- 208000018675 Schwartz-Jampel syndrome Diseases 0.000 description 11
- 125000003118 aryl group Chemical group 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 7
- 229960003459 allopurinol Drugs 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- 102000054766 genetic haplotypes Human genes 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 229960002036 phenytoin Drugs 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 125000000547 substituted alkyl group Chemical group 0.000 description 5
- 125000003107 substituted aryl group Chemical group 0.000 description 5
- 208000010201 Exanthema Diseases 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 244000187656 Eucalyptus cornuta Species 0.000 description 3
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 229940125681 anticonvulsant agent Drugs 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 2
- 108091092584 GDNA Proteins 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 102100035683 Axin-2 Human genes 0.000 description 1
- 101700047552 Axin-2 Proteins 0.000 description 1
- 101100490563 Caenorhabditis elegans adr-1 gene Proteins 0.000 description 1
- 101100388220 Caenorhabditis elegans adr-2 gene Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 1
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 101001024425 Mus musculus Ig gamma-2A chain C region secreted form Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000032509 Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum Diseases 0.000 description 1
- 244000028419 Styrax benzoin Species 0.000 description 1
- 235000000126 Styrax benzoin Nutrition 0.000 description 1
- 235000008411 Sumatra benzointree Nutrition 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 208000019502 Thymic epithelial neoplasm Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000005325 aryloxy aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002130 benzoin Drugs 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- -1 carboxy carboxy Chemical group 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 208000004526 exfoliative dermatitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 101150027973 hira gene Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000001145 hydrido group Chemical class *[H] 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940061414 trileptal Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80012106P | 2006-05-11 | 2006-05-11 | |
| PCT/US2007/068782 WO2007134235A2 (en) | 2006-05-11 | 2007-05-11 | Hla alleles associated with adverse drug reactions and methods for detecting such |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL194900A0 IL194900A0 (en) | 2009-08-03 |
| IL194900A true IL194900A (en) | 2013-02-28 |
Family
ID=38694734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL194900A IL194900A (en) | 2006-05-11 | 2008-10-23 | HLA allele gene associated with drug antagonism and methods for detecting it |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7943309B2 (enExample) |
| EP (1) | EP2016198B1 (enExample) |
| JP (1) | JP2009536828A (enExample) |
| KR (1) | KR101450348B1 (enExample) |
| CN (1) | CN101454462A (enExample) |
| AU (1) | AU2007249225B2 (enExample) |
| BR (1) | BRPI0710436A8 (enExample) |
| CA (1) | CA2651954C (enExample) |
| DK (1) | DK2016198T3 (enExample) |
| ES (1) | ES2422735T3 (enExample) |
| IL (1) | IL194900A (enExample) |
| MY (1) | MY150648A (enExample) |
| NZ (2) | NZ597628A (enExample) |
| PL (1) | PL2016198T3 (enExample) |
| PT (1) | PT2016198E (enExample) |
| TW (1) | TWI335937B (enExample) |
| WO (1) | WO2007134235A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1536021A1 (en) * | 2003-11-27 | 2005-06-01 | Consortium National de Recherche en Genomique (CNRG) | Method for HLA typing |
| US8927462B2 (en) | 2010-04-12 | 2015-01-06 | Academia Sinica | Method for identifying HLA complexes associated with adverse drug reactions |
| WO2012174723A1 (en) * | 2011-06-23 | 2012-12-27 | Chang Gung Medical Foundation Chang Gung Memorial Hospital at Keelung | Risk assessment for phenytoin-induced adverse drug reactions |
| CN102296109A (zh) * | 2011-06-30 | 2011-12-28 | 北京思尔成生物技术有限公司 | HLA-B*1502基因的SYBR Green I检测方法及其专用引物与试剂盒 |
| US20150225788A1 (en) | 2011-12-12 | 2015-08-13 | Wen-Hung Chung | Risk assessment for phenytoin-induced adverse drug reactions |
| CN102660635B (zh) * | 2012-01-14 | 2014-03-12 | 长沙三济生物科技有限公司 | 一种定性检测hla-b*1502基因亚型的荧光pcr试剂盒 |
| CN103114138B (zh) * | 2013-01-27 | 2014-12-03 | 复旦大学 | Pcr-ssp法定性检测hla-b*1502基因的方法及临床试剂盒 |
| CN105722999A (zh) * | 2013-09-17 | 2016-06-29 | 新加坡科技研究局 | 检测遗传变体的方法 |
| CN104017898B (zh) * | 2014-06-25 | 2016-04-27 | 上海荻硕贝肯生物科技有限公司 | 快速检测hla-b*5801等位基因的引物、试剂盒及方法 |
| CN104232781B (zh) * | 2014-09-26 | 2017-04-19 | 陕西佰美基因股份有限公司 | 一种检测HLA‑B*5801等位基因的TaqMan探针实时荧光PCR方法 |
| CN106119362B (zh) * | 2016-06-30 | 2019-09-10 | 江苏伟禾生物科技有限公司 | 一种用于检测hla-b*1502等位基因的引物组及试剂盒 |
| CN108929902B (zh) * | 2018-07-28 | 2022-03-25 | 北京博奥晶典生物技术有限公司 | 用于检测等位基因hla-b*5801的肽核酸引物组合物、试剂盒及方法 |
| CN109355358A (zh) * | 2018-10-22 | 2019-02-19 | 江苏美因康生物科技有限公司 | 一种快速高效检测药源性皮肤不良反应相关基因多态性的试剂盒及方法 |
| CN109554460B (zh) * | 2018-12-17 | 2022-03-22 | 上海市疾病预防控制中心 | 一种基于hla基因多态性位点预测h7n9易感人群的检测方法及其用途 |
| TWI804620B (zh) * | 2019-05-06 | 2023-06-11 | 長庚醫療財團法人林口長庚紀念醫院 | 評估疾病調節抗風濕藥物引發嚴重皮膚藥物不良反應風險的方法、其檢測套組及其用途 |
| US20220259655A1 (en) * | 2019-05-06 | 2022-08-18 | Chang Gung Memorial Hospital, Linkou | Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof |
| CN111620924A (zh) * | 2020-06-04 | 2020-09-04 | 华中农业大学 | 基于天然产物的药物设计方法、五环三萜类化合物、其制备方法及应用 |
| CN113308532A (zh) * | 2021-05-28 | 2021-08-27 | 上海康黎诊断技术有限公司 | 一种用于检测人hla-b*1502基因突变的特异性引物探针组合及其试剂盒，以及方法 |
| WO2023080478A1 (ko) * | 2021-11-02 | 2023-05-11 | 주식회사 랩 지노믹스 | Ｈｌａ－ｂ＊5801 대립유전자 검출용 핵산 분자 및 이를 이용한 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5583238A (en) * | 1990-11-19 | 1996-12-10 | G. D. Searle & Co. | Method for making intermediates useful in synthesis of retroviral protease inhibitors |
| US5883238A (en) * | 1993-03-18 | 1999-03-16 | N.V. Innogenetics S.A. | Process for typing HLA-B using specific primers and probes sets |
| US5550039A (en) | 1995-03-07 | 1996-08-27 | Hoffmann-La Roche Inc. | Oligonucleotide primers for HLA class I B locus DNA typing |
| US6583139B1 (en) | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| BRPI0407569A (pt) * | 2003-02-17 | 2006-02-14 | Novartis Ag | uso de s-10-hidróxi-10, 11-diidro-carbamazepina para o tratamento de ansiendade e distúrbios bipolares |
| US7470513B2 (en) * | 2003-11-10 | 2008-12-30 | Academia Sinica | Risk assessment for adverse drug reactions |
-
2007
- 2007-05-11 ES ES07797432T patent/ES2422735T3/es active Active
- 2007-05-11 CA CA2651954A patent/CA2651954C/en active Active
- 2007-05-11 WO PCT/US2007/068782 patent/WO2007134235A2/en not_active Ceased
- 2007-05-11 DK DK07797432.7T patent/DK2016198T3/da active
- 2007-05-11 US US11/747,674 patent/US7943309B2/en active Active
- 2007-05-11 PL PL07797432T patent/PL2016198T3/pl unknown
- 2007-05-11 BR BRPI0710436A patent/BRPI0710436A8/pt not_active Application Discontinuation
- 2007-05-11 KR KR1020087027562A patent/KR101450348B1/ko active Active
- 2007-05-11 NZ NZ597628A patent/NZ597628A/xx not_active IP Right Cessation
- 2007-05-11 CN CNA2007800170212A patent/CN101454462A/zh active Pending
- 2007-05-11 JP JP2009510183A patent/JP2009536828A/ja active Pending
- 2007-05-11 MY MYPI20084331 patent/MY150648A/en unknown
- 2007-05-11 TW TW096116910A patent/TWI335937B/zh active
- 2007-05-11 NZ NZ572259A patent/NZ572259A/en not_active IP Right Cessation
- 2007-05-11 AU AU2007249225A patent/AU2007249225B2/en not_active Ceased
- 2007-05-11 EP EP07797432.7A patent/EP2016198B1/en not_active Revoked
- 2007-05-11 PT PT77974327T patent/PT2016198E/pt unknown
-
2008
- 2008-10-23 IL IL194900A patent/IL194900A/en active IP Right Grant
-
2011
- 2011-05-04 US US13/100,665 patent/US8142999B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MY150648A (en) | 2014-02-14 |
| ES2422735T3 (es) | 2013-09-13 |
| AU2007249225A1 (en) | 2007-11-22 |
| WO2007134235A3 (en) | 2008-01-17 |
| CA2651954A1 (en) | 2007-11-22 |
| EP2016198B1 (en) | 2013-05-01 |
| DK2016198T3 (en) | 2013-07-15 |
| KR20090031671A (ko) | 2009-03-27 |
| BRPI0710436A8 (pt) | 2018-06-26 |
| AU2007249225B2 (en) | 2013-06-27 |
| CN101454462A (zh) | 2009-06-10 |
| US20080145846A1 (en) | 2008-06-19 |
| WO2007134235A2 (en) | 2007-11-22 |
| KR101450348B1 (ko) | 2014-10-14 |
| TWI335937B (en) | 2011-01-11 |
| CA2651954C (en) | 2014-02-25 |
| IL194900A0 (en) | 2009-08-03 |
| US20110212439A1 (en) | 2011-09-01 |
| NZ572259A (en) | 2012-03-30 |
| EP2016198A2 (en) | 2009-01-21 |
| PL2016198T3 (pl) | 2013-12-31 |
| JP2009536828A (ja) | 2009-10-22 |
| PT2016198E (pt) | 2013-07-29 |
| BRPI0710436A2 (pt) | 2012-10-09 |
| TW200844238A (en) | 2008-11-16 |
| US8142999B2 (en) | 2012-03-27 |
| NZ597628A (en) | 2013-07-26 |
| EP2016198A4 (en) | 2010-07-21 |
| US7943309B2 (en) | 2011-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL194900A (en) | HLA allele gene associated with drug antagonism and methods for detecting it | |
| KR20170035860A (ko) | 보습 피부 타입 유전자 다형성 마커 및 이의 용도 | |
| TW201713776A (zh) | Ｈｌａ－ｂ＊１５：０２中的單一核苷酸多型性及其用途 | |
| KR20150017149A (ko) | 약물 부작용과 관련된 ＨＬＡ 대립유전자의 ｔＳＮＰ를 이용한 고속 검출 방법 | |
| CA3163367A1 (en) | Biomarkers and uses thereof in the treatment of chronic hepatitis b infection | |
| CA2468312A1 (en) | Single nucleotide polymorphisms and combinations thereof predictive for paclitaxel responsiveness | |
| KR20170051747A (ko) | 피부 주름 발생 민감도 진단용 단일염기다형성 마커 및 이의 용도 | |
| WO2016057852A1 (en) | Markers for hematological cancers | |
| Liu et al. | A multiplex allele‐specific real‐time polymerase chain reaction assay for HLA‐B* 13: 01 genotyping in four Chinese populations | |
| Jung et al. | Development of HLA-B* 57: 01 genotyping real-time PCR with optimized hydrolysis probe design | |
| Middleton | HLA typing from serology to sequencing era | |
| US20040126794A1 (en) | Detection of susceptibility to autoimmune diseases | |
| TW201533244A (zh) | 檢測酒精代謝基因之方法及套組 | |
| JP6516128B2 (ja) | 抗甲状腺薬誘発性無顆粒球症リスクを判定するための検査方法及び判定用キット | |
| JP6082693B2 (ja) | 喫煙感受性加齢黄斑変性易罹患性の判定方法及び判定キット | |
| KR20170051748A (ko) | 피부 보습 진단용 단일염기다형성 마커 및 이의 용도 | |
| JP2010162020A (ja) | 新規ｈｌａ−ｄｒｂ１遺伝子およびその用途 | |
| HK1134325A (en) | Hla alleles associated with adverse drug reactions and methods for detecting such | |
| JP2014045744A (ja) | 原発性胆汁性肝硬変の発症リスク予測マーカー、プローブ、プライマー及びキット並びに原発性胆汁性肝硬変の発症リスク予測方法 | |
| WO2006068111A1 (ja) | ＰＰＡＲγ遺伝子の遺伝子多型に関連する表現型の判定方法 | |
| JP2011050377A (ja) | 新規ｈｌａ−ｄｒｂ１遺伝子およびその用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |